NewEdge Advisors LLC Sells 18,291 Shares of Abbott Laboratories $ABT

NewEdge Advisors LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 6.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 270,877 shares of the healthcare product maker’s stock after selling 18,291 shares during the period. NewEdge Advisors LLC’s holdings in Abbott Laboratories were worth $27,811,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of ABT. J. Stern & Co. LLP increased its stake in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Norges Bank bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $2,938,892,000. Arrowstreet Capital Limited Partnership increased its position in shares of Abbott Laboratories by 217.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock worth $566,967,000 after acquiring an additional 3,780,402 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Abbott Laboratories by 303.0% during the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after acquiring an additional 3,330,368 shares during the period. Finally, Ninety One UK Ltd bought a new stake in Abbott Laboratories in the 4th quarter valued at $336,815,000. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Barclays lowered their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. Weiss Ratings cut Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 23rd. Wells Fargo & Company lifted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. boosted their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Finally, Benchmark decreased their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $118.17.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $107.81 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The business has a 50-day moving average of $95.51 and a 200-day moving average of $100.03. The stock has a market capitalization of $186.56 billion, a price-to-earnings ratio of 34.89, a PEG ratio of 2.09 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Diagnostics expansion strengthens growth outlook: Abbott is broadening its Diagnostics growth base through its Exact Sciences relationship and oncology testing expansion. Gains in cancer diagnostics and resilient routine testing are helping offset weaker respiratory-related demand, potentially making growth less dependent on COVID and respiratory testing. Here’s How ABT Broadens Diagnostics Growth Base With Oncology Expansion
• Positive Sentiment: Analysts remain bullish: Although ABT has lagged the broader market over the past year, Wall Street analysts continue to view the stock favorably and see further upside potential based on Abbott’s diversified healthcare portfolio and earnings durability. Abbott Stock: Is Wall Street Bullish or Bearish?
• Positive Sentiment: Reliable-growth investment case: An investor letter from Matrix Asset Advisors presents Abbott as a compelling long-term healthcare holding, emphasizing its dependable growth profile and diversified end markets. Broader nutritional-market growth could also support Abbott’s nutrition business over time. What Makes Abbott Laboratories a Compelling Investment Opportunity Global Nutritional Market Outlook
• Neutral Sentiment: Value debate remains: Comparisons with Envista (NVST) focus on which medical-products stock offers better value. The coverage may prompt investors to weigh Abbott’s premium valuation against its stronger diversification and consistency, but it does not represent a new company-specific catalyst. NVST vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Competitive backdrop: Analysts’ discussion of Abbott alongside other healthcare companies provides sector context, but no major change to Abbott’s outlook is indicated. Boston Scientific’s reduced 2026 guidance could be relatively favorable for Abbott if investors rotate toward companies with steadier execution, though it also underscores competitive pressures in medical devices. Analysts Offer Insights on Healthcare Companies

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.